Ocular Therapeutix
OCUL
132 hedge funds and large institutions have $215M invested in Ocular Therapeutix in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 44 increasing their positions, 43 reducing their positions, and 24 closing their positions.
2.47% more ownership
Funds ownership: 54.21% → 56.68% (+2.5%)
2% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 43
6% less funds holding
Funds holding: 140 → 132 (-8)
13% less call options, than puts
Call options by funds: $771K | Put options by funds: $883K
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
25% less capital invested
Capital invested by funds: $288M → $215M (-$73.2M)
33% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.45M |
| 2 |
Millennium Management
New York
|
+$2.46M |
| 3 |
Renaissance Technologies
New York
|
+$2.39M |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
+$1.94M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$1.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.11M |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$831K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$797K |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$747K |
| 5 |
Man Group
London,
United Kingdom
|
-$746K |
OCUL Hedge Fund Activity: Q1 2022 in Review
132 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2022, worth a combined $215M — down 25% from $288M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of OCUL and 16 opened new positions — a net loss of 8 holders — while 43 trimmed existing stakes and 44 added.
The largest buyer was Federated Hermes, opening a new position worth an estimated $3.45M. The largest seller was Morgan Stanley, cutting an estimated $1.11M.
- 132 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2022, down from 140 in Q4 2021.
- Funds reported $215M of Ocular Therapeutix stock for Q1 2022, down 25% quarter-over-quarter.
- 16 funds opened new Ocular Therapeutix positions in Q1 2022 and 24 closed out, a net change of -8 holders.
- The largest Ocular Therapeutix buyer in Q1 2022 was Federated Hermes, an estimated $3.45M added.
- The largest Ocular Therapeutix seller in Q1 2022 was Morgan Stanley, an estimated $1.11M sold.
Based on aggregated 13F filings for Q1 2022.